Prot #BST002: A Phase 2b, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly-Diagnosed Acute Myeloid Leukemia, Not Eligible for Standard Induction Therapy

Project: Research project

StatusActive
Effective start/end date10/29/1810/29/21

Funding

  • PRA Health Sciences (Prot #BST002)
  • BioSight Ltd. (Prot #BST002)